School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Design Therapeutics, Inc. DSGN

Healthcare · Biotechnology

$11.65last close 2026-10-09 · market cap $729.08M · delayed data

Trailing returns

1M-22.44%
3M-24.45%
6M-6.73%
1Y+63.62%

Basis: Adjusted daily closes.

What it does

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.

Open DSGN in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies